anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Van der Woude syndrome (VWS) is a rare congenital malformation characterized by lower lip pits among patients with a lip and/or palate cleft. It is transmitted by an autosomal dominant inheritance with variable expressivity.
METHODS: The study group consisted of 24 consecutive patients (13 males and 11 females) with VWS operated on at a single center between 2009 and 2022. They suffered from: bilateral cleft lip and palate - 6 patients; unilateral cleft lip and palate - 9 patients; cleft lip - 1 patient; and isolated cleft palate - 8 patients.
RESULTS: In 16 (66%) cases pits of lower lip occurred on both side of midline, while in 8 (34%) the pits were detected unilaterally. The primary cleft repairs were performed according to one-stage principle at the mean age of 8.6 months (SD 1.4, range 6-12). In all patients lower lip pits repairs were performed after the primary cleft repairs as a separate procedure at the mean age of 37 months (SD 11.3 range 14-85). The mean number of all primary repairs of the syndrome-both cleft defect and lower lip pits repairs-was 2.46. Nine patients (37.5%) required additional secondary corrections of the lower lip due to the poor aesthetic post-operative outcome.
CONCLUSIONS: The frequent need for secondary corrections of residual lower lip deformities indicates the considerable difficulties in obtaining a satisfactory outcome of the repairs to lip pits caused by VWS. The average number of the primary surgical interventions in evaluated material remained low.
VHS with one general trigger: "If I am getting angry..." and 10 strategies (e.g. "Then I will take deep breaths"). Participants are instructed to link trigger with strategies.
Sepsis-associated liver dysfunction (SALD) aggravates the disease progression and prognosis of patients. Macrophages in the liver play a crucial role in the occurrence and development of SALD. Human umbilical cord mesenchymal stem cells (MSCs), by secreting extracellular vesicles (EVs), show beneficial effects in various inflammatory diseases. However, whether MSC-derived EVs (MSC-EVs) could ameliorate the inflammatory response in liver macrophages and the underlying mechanisms remain unclear. In this study, a mouse model of sepsis induced by lipopolysaccharide (LPS) challenge was used to investigate the immunomodulatory functions of MSC-EVs in SALD. LPS-stimulated primary Kupffer cells (KCs) and Raw264.7 were used to further explore the potential mechanisms of MSC-EVs in regulating the inflammatory response of macrophages. The results showed that MSC-EVs alleviated liver tissue injury and facilitated the polarization of M1 to M2 macrophages. Further in vitro studies confirmed that MSC-EVs treatment significantly downregulated the expression of several enzymes related to glycolysis and reduced the glycolytic flux by inhibiting hypoxia-inducible factor 1α (HIF-1α) expression, thus effectively inhibiting the inflammatory responses of macrophages. These findings reveal that the application of MSC-EVs might be a potential therapeutic strategy for treating SALD.
CD24 is overexpressed in various tumours and considered a regulator of cell migration, invasion, and proliferation. Recent studies have found that CD24 on ovarian cancer (OC) and triple-negative breast cancer cells interacts with the inhibitory receptor sialic-acid-binding Ig-like lectin 10 (Siglec-10) on tumour-associated macrophages (TAMs) to inhibit phagocytosis by macrophages. Because of its multiple roles in regulating the immune response and tumorigenesis, CD24 is a very promising therapeutic target. However, the regulatory mechanism of CD24 in OC remains unclear. Here, we found that the long noncoding RNA (lncRNA) IL21-AS1, which was upregulated in OC, inhibited macrophage-mediated phagocytosis and promoted OC cell proliferation and apoptosis inhibition. More importantly, after IL21-AS1 knockdown, a significant survival advantage was observed in mice engrafted with tumours. Mechanistically, we identified IL21-AS1 as a hypoxia-induced lncRNA. Moreover, IL21-AS1 increased HIF1α-induced CD24 expression under hypoxic conditions. In parallel, we found that IL21-AS1 acted as a competing endogenous RNA (ceRNA) for miR-561-5p to regulate CD24 expression. Finally, IL21-AS1 increased CD24 expression in OC and facilitated OC progression. Our findings provide a molecular basis for the regulation of CD24, thus highlighting a potential strategy for targeted treatment of OC.
Crude extracts containing cardiac substances are purified by precipitating the active substances with heavy metal compounds such as copper, silver, lead or mercury salts, with or without the addition of other salts such as sodium acetate or magnesium salts, and subsequently removing the precipitant.  Examples of the invention are as follows: (1) the mother liquor, remaining after the precipitation of blood-sugar level reducing substances with ammonium sulphate from pancreas extract, is mixed with acetone; 500 c.c. of the aqueous layer which forms is diluted to 2 litres, 100 gms. of sodium acetate and 160 c.c. of 40 per cent sodium bisulphite solution added and the mixture boiled; 10 per cent copper sulphate is then added until no more precipitate forms; the liquid is boiled for three minutes, filtered hot, the precipitate suspended in water, slightly acidified and the copper precipitated with hydrogen sulphide; the filtered solution is evaporated in vacuo and the residue dissolved in water, neutralized and standardized: (2) organic phosphorus-containing substances are removed from the product of (1) by precipitation with magnesia mixture, and the filtrate is treated with excess magnesia mixture and ammoniacal silver nitrate; the precipitate is separated, washed with ammonia, suspended in water, and the silver precipitated with hydrochloric acid; the precipitate is filtered off and the filtrate evaporated in vacuo and redissolved: (3) a mother liquor as in (1) is diluted, precipitated with 10 per cent copper sulphate solution in the presence of sodium acetate and sodium bisulphite, and worked up as in (1): (4) the product of the example of Specification 279,445, [Class 81 (i), Disinfecting &c.], is precipitated with 80 per cent copper sulphate solution in the presence of sodium acetate and sodium bisulphite and further worked up as in (1): (5) the product of example (1) of Specification 335,202, [Class 81 (i), Disinfecting &c.], is treated as in (2) : (6) the product of the process of Specification 359,523 is treated as in (1) : (7) the product of example (1) is treated with solid cuprous chloride while boiling and further worked up as in (1) : (8) the product of the example of Specification 279,445 is rendered slightly ammoniacal and precipitated with 25 per cent lead acetate solution, filtered, and the lead removed from the precipitate, ground in water, by treatment with 20 per cent sulphuric acid; traces of lead are removed from the filtrate with hydrogen sulphide: (9) the product of example (1) of Specification 335,202 is treated with mercuric chloride solution and the mercury removed from the precipitate with hydrogen sulphide.  Specifications 306,606 and 306,608, [both in Class 81 (i), Disinfecting &c.], also are referred to.
The present disclosure describes imaging systems configured to determine the accuracy of anatomical measurements obtained from image data. Systems may include an ultrasound transducer configured to acquire echo signals responsive to ultrasound pulses transmitted toward a target region. Systems can also include a graphical user interface configured to display a biometry tool widget, such as a caliper, for acquiring a measurement of an anatomical feature within the target region from at least one image frame generated from the ultrasound echoes. Systems can also include one or more processors configured to determine a confidence metric indicative of the accuracy of the measurement. The processors can also be configured to cause the graphical user interface to display a graphical indicator corresponding to the confidence metric. The processors can implement one or more neural networks, and can derive additional information, such as gestational age or weight, from the anatomical measurements acquired.
Approximately 3 months after postmastectomy radiation therapy, the preserved, irradiated, and re-inflated breast skin will be used to perform the delayed breast reconstruction. During the stage 2 reconstruction, the implant or expander will be removed and the definitive reconstruction will be performed with the preserved breast skin utilizing a preference for autologous tissue or autologous tissue with an implant due to the potential for complications with implant-based reconstructions after radiation therapy (XRT).
OBJECTIVES: Proliferative verrucous leukoplakia (PVL) is a rare but highly aggressive variant of oral leukoplakia that almost inevitably progresses to oral squamous cell carcinoma (OSCC). The aims of this study were to perform whole exome sequencing of a cohort of patients diagnosed with PVL and identify potential mutational profiles and pathways in this disorder.
STUDY DESIGN: A total of 12 oral cavity mucosal biopsies from 6 patients with oral lesions clinically compatible with PVL were used. Of these, 9 were diagnosed as dysplasia, 1 OSCC, and 2 hyperkeratosis/hyperplasia. Exome sequencing used the Ion AmpliSeq Exome platform. Ion Reporter software was used for variant calling, annotation, and filtering. Analysis and visualization of somatic mutations was carried out using the MAFtools R package.
RESULTS: Following exome sequencing and mutational profiling, we analyzed the profiles for cancer associated genes and signatures. Genes previously associated with OSCC, including HYDIN, MUC16, MAML3, CDKN2A, FAT1, and CASP8, were mutated in multiple samples. Several DNA damage repair genes including PARP1 were mutated in PVL samples. NOTCH and Hippo pathways were the most frequently impacted by mutation.
CONCLUSIONS: This genome wide characterization of premalignant PVL identifies both known and potentially novel oncogenic mechanisms in this disorder.
A personal anatomy card includes a card member and a machine-readable storage medium integrated in the card member. Machine-readable data including compressed data representative of a three-dimensional model of a portion of the individual is stored on the machine-readable storage medium. The three-dimensional model is formed by tomographically creating a plurality of two-dimensional cross-sectional images of a portion of the individual, processing the plurality of two-dimensional cross-sectional images to form data representative of the three-dimensional model, and compressing the data to form the compressed data. Optionally, a three-dimensional data player is integrated in the card member. The three-dimensional data player includes a display device, a user interface, and a processor. The processor is operative to decode the compressed data in dependence upon navigation instructions received by the user interface to command the display device to display a selected portion of the three-dimensional model.
Arterial ischemic stroke outcomes benefited from the implementation of recanalization treatments (IV thrombolysis, endovascular treatments) and adapted management pathways in adult patients. Nevertheless randomized trials did not enroll patients under the age of 18 years old and data concerning these treatments in children are scarce. As it is much less frequent than in adults, recognition of stroke is often delayed in children. Consequently, acute phase trials are difficult to set up and perform. The phase I multicentric international prospective trial TIPS (Thrombolysis in Pediatric Stroke) was prematurely stopped because of poor enrollment. Published retrospective regional (Paris-Ile-de-France region, France) and national (Switzerland) studies addressed the feasibility of such treatments but, because of small samples (less than 20 patients in each study), efficiency and prognostic factors could not be addressed.

Exhaustive retrospective studies in a definite geographic area but with a sufficient number of patients in a limited inclusion period would provide these crucial data and address these questions with good relevance and limited bias.
<P>PROBLEM TO BE SOLVED: To provide a means for enhancing the bioavailability of a sparingly soluble material in a skin care preparation for external use.  <P>SOLUTION: This skin care preparation for external use is obtained by dispersing a matrix containing the sparingly soluble material containing heterocyclic compounds, a glycoside of a substance having a hydrophobic nucleus, a triterpene or its derivative and alcohols containing a 12-24C aliphatic saturated alcohol or a phytosterol in an amount of 1-5 pts. wt. based on 1 pt. wt. sparingly soluble material into a vehicle.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
PCT No. PCT/US95/03998 Sec. 371 Date Oct. 25, 1996 Sec. 102(e) Date Oct. 25, 1996 PCT Filed Apr. 5, 1995 PCT Pub. No. WO95/30019 PCT Pub. Date Nov. 9, 1995Disclosed are vaccines containing both a DNA sequence encoding FIV gag protein and a DNA sequence encoding FIV env protein. The gag and env proteins are preferably expressed by baculovirus expression systems containing the DNA sequences encoding the FIV env and gag proteins or in feline herpes virus vectors containing the DNA sequences encoding the FIV env and gag proteins. Also disclosed are combined mucosal/parenteral, mucosal/mucosal and parenteral/parenteral inoculation methods.
Physiological abnormalities in pulmonary granulomas-pathological hallmarks of tuberculosis (TB)-compromise the transport of oxygen, nutrients, and drugs. In prior studies, we demonstrated mathematically and experimentally that hypoxia and necrosis emerge in the granuloma microenvironment (GME) as a direct result of limited oxygen availability. Building on our initial model of avascular oxygen diffusion, here we explore additional aspects of oxygen transport, including the roles of granuloma vasculature, transcapillary transport, plasma dilution, and interstitial convection, followed by cellular metabolism. Approximate analytical solutions are provided for oxygen and glucose concentration, interstitial fluid velocity, interstitial fluid pressure, and the thickness of the convective zone. These predictions are in agreement with prior experimental results from rabbit TB granulomas and from rat carcinoma models, which share similar transport limitations. Additional drug delivery predictions for anti-TB-agents (rifampicin and clofazimine) strikingly match recent spatially-resolved experimental results from a mouse model of TB. Finally, an approach to improve molecular transport in granulomas by modulating interstitial hydraulic conductivity is tested in silico.
LHWs undergo training over 3 days and recruit 15 participants from their social network. Participants attend a lecture on healthy nutrition for cardiovascular health presented by a professional health educator at months 1 and 3. After the first meeting, participants receive a brochure on CRC screening. Participants receive phone calls from the LHW at months 2 and 4 regarding changes in their nutritional behavior. Participants may attend an optional post-intervention LHW outreach session on CRC screening.
Unintended pregnancy for female patients with chronic myeloid leukemia (CML) raises the discussion of treatment choices due to the teratogenicity of tyrosine kinase inhibitor (TKI). We report 51 accidental pregnant CML chronic phase (CP) patients with TKI withdrawal immediately after pregnancy from December 2010 to February 2024 to observe the effect of short exposure to TKI on the fetus and the infant outcomes. 59 pregnancies resulted in 100% normal childbirth without birth abnormalities. The median TKI exposure duration was 4 (4-20) weeks in 58 pregnancies, and one pregnancy avoided TKI exposure due to treatment discontinuation of the patient with treatment-free remission (TFR). All newborns had normal birth weight except one premature infant with low birth weight less than the 10th percentile. Up to now, all the children are in good health. 13 (25.5%) and 30 (58.8%) patients had achieved major molecular response (MMR) and deep molecular response (DMR) at pregnancy, respectively. After TKI discontinuation, loss of MMR and complete hematologic response occurred in 6 (46.2%) and 2 (25.0%) patients at delivery, respectively. 38 patients resumed TKI treatment after delivery, and 13 patients without DMR loss sustained TFR after delivery. The median time to regain MMR and DMR were 3 (2-6) months and 6 (1-28) months, respectively. These results demonstrate that TKI discontinuation during pregnancy is feasible for CML-CP patients, and short TKI exposure of pregnant patients has little influence on children's growth and development.
TEC Group received received treatment with Envafolimab in combination with Etoposide and Carboplatin for 6 cycles. Prior to each chemotherapy cycle, they were given Trilaciclib before each chemotherapy session. After 6 cycles, they were treated with Trilaciclib in combination with Envafolimab as maintenance therapy until disease progression, intolerable adverse reactions, or withdrawal of informed consent by the patient occurred, with a maximum duration not exceeding 2 years.
BACKGROUND: Respiratory virus infections are extremely common in young children. These infections typically lead to inflammation and constriction of the airways, which is termed bronchiolitis. Bronchiolitis is the leading cause of hospitalization for infants with respiratory infections, with an average of 120,000 children under the age of one hospitalized every year. Viral infection by Respiratory Syncytial Virus (RSV), rhinoviruses, or influenza viruses is thought to be by far the major driver of bronchiolitis. The children who need to be hospitalized with bronchiolitis have a drastically increased chance (about 45%) of developing chronic respiratory diseases such as wheezing or asthma. The disease of asthma affects children more than adults, and the Centers For Disease Control states that asthma is the most chronic condition among children under the age of 18, affecting more than 6 million (or 8.4%) children in the US. Due to this prevalence, asthma is the third leading cause of hospitalization among children under the age of 15 years, with the annual direct healthcare costs at \~$50 billion every year. The economic costs associated with parental lost productivity is another \~$6 billion every year. The American Lung Association states that asthma is also one of the leading causes of school absenteeism, with an estimated 13.8 million lost school days every year. While asthma can be managed with bronchodilator inhalers, there is not a single treatment designed to prevent or reverse asthma disease. Understanding how viral infection causes initial bronchiolitis and maintains the chronic inflammation that leads to asthma will lead to new treatments that prevent or reverse chronic lung diseases. This research has the potential to change everyday life for millions of children and their families in the US.
PURPOSE:An agent against mutagenesis important for preventing carcinogenesis, deactivating mutagenesis, containing coenzume A, a type present in vivo of pantothenic acid, as an active ingredient. CONSTITUTION:An agent against mutagenesis containing coenzyme A such as a compound shown by the formula I as an active ingredient. Coenzyme A inhibits completely mutagenesis of N-methyl-N'-nitro-N-nitrosoguanidine, a carcinostatic substance in the stomach and the intestine, when 150 times as much the compound shown by the formula I as the nitrosoguanidine by molar amount is used. It also deactivates 90wt% benz[a]pyrene having strong carcinogenesis on the liver and the skin when 10 times as much the compound as benz[a]pyrene by molar amount is used. Namely, coenzyme A is found to deactivate mutagenesis of carcinostatic substance and effective as an agent against mutagenesis. Coenzyme A is a type present in vivo of pantothenic acid shown by the formula II, safe, has effects as vitamin, and is usable in the field of drug and food.
Hair care agent, comprises natural materials comprising vegetables, fruits, honey, coffee and eggs. An independent claim is also included for preparing the hair care agent, comprising crushing the solid components of the natural materials individually or together and stirring with the remaining natural materials to a homogeneous mass. ACTIVITY : Endocrine-Gen. The endocrine-gen activity of the hair care agent was tested by applying to the freshly washed hair of the subject, which was severely damaged by frequent hair dyeing and was thin due to the hair fall and age of the subject, 3 times per week respectively for 3 weeks. The results showed that the hair became thicker, stronger and shinier without hair fall. MECHANISM OF ACTION : None given.
OBJECTIVE: This investigation aimed to delineate the clinical manifestations associated with high-altitude pulmonary edema (HAPE) and acute mountain sickness (AMS) in pediatric populations and find the risk factors of HAPE.
METHODS: We conducted a retrospective analysis of clinical data from children under 18 years diagnosed with HAPE and AMS at an average altitude of 3000 m. The clinical data between these two groups were compared.
RESULTS: The study encompassed 74 pediatric patients, 27 with AMS and 47 with HAPE. HAPE presentations included classic HAPE (55.3%), reentry HAPE (27.7%), and high-altitude resident pulmonary edema (HARPE, 17.0%). Notably, 87.2% of HAPE cases were male, and 68.1% had a high body mass index (BMI). HARPE instances followed viral infections, prominently SARS-CoV-2. HAPE cases exhibited higher BMI, respiratory tract infections within 1 week preceding symptom onset, an increase in white blood cell counts (WBCs), lower peripheral arterial oxygen saturation (SpO2), and higher heart rate compared to the AMS group. Multivariate logistic regression pinpointed high BMI as an independent HAPE risk factor (odds ratio = 19.389, 95% confidence interval: 1.069-351.759, p = .045).
CONCLUSION: HAPE occurs predominantly in males, with high BMI identified as a critical independent risk factor. The study underscores the need for heightened awareness and preventive strategies against HAPE in children at high altitudes.
Excessive gestational weight gain (GWG) increases risks for pregnancy complications, postpartum weight retention and offspring obesity. Traditional intervention programs are time and cost intensive. Mobile technology (mHealth) has been successful for weight loss and behavior changes; however, their use in pregnancy need to be further examined. This study aims to evaluate the impact of a smartphone application (app) intervention on GWG, diet, physical activity and glucose homeostasis.

HealthyMoms is a randomized controlled trial recruiting women at the first maternity clinic visit (week 6-10) in the Linköping area, Sweden. Women will be randomized to the control or intervention group (n=150 per group). All women will receive standard care. The intervention group will also receive the HealthyMoms smartphone app promoting healthy eating, activity and GWG during 6 months. Pregnancy outcomes are GWG (primary), food intake (web-based questionnaire), fat mass (BodPod), glucose homeostasis, activity (accelerometer) in week 37. Maternal and infant body fatness will be assessed one week post partum.